newsfilter
← Earnings
Earnings Releases·

Rigel Pharmaceuticals — Third Quarter 2026 Earnings Summary

Rigel Pharmaceuticals reported third-quarter 2026 total revenues of $80.9 million, driven by $72.3 million in net product sales and $8.6 million in contract revenues. The company's new product, VEPPANU, generated $6.6 million in sales during its first six weeks of commercial availability in August. Net income for the quarter was $13.2 million, or $0.70 per basic share, while total costs and expenses rose to $63.8 million due to increased research and development and commercial launch expenses. Rigel has updated its full-year 2026 revenue guidance to approximately $290 to $295 million, excluding VEPPANU sales.

Company
RIGEL PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology